Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14759636 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL2724494 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL15209157 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL15472172 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL4561383 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL14889709 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL14900455 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL15472141 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL15472173 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL2724728 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635265-B1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS INC (US) | 2018-04-04 | — | — | EP | claimed |
| US-9067882-B2 | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | claimed |
| EP-2635265-A2 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | Merck Sharp & Dohme Corp. (US) | 2013-09-11 | — | — | EP | claimed |
| US-20130225836-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2013-08-29 | — | — | US | claimed |
| WO-2012061259-A2 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | WO | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2023122752-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023044333-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-10337014-B2 | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-2635265-B1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180037893-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-9067882-B2 | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130225836-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225836-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | LPAR2 25/4885LPAR3 5/4885LPAR1 14/4885 |
| US-10337014-B2 | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | LDLR, APOB, CETP | LPAR2 18/4885LPAR3 4/4885LPAR1 13/4885 |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | LPAR2 173/4885LPAR3 199/4885LPAR1 262/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | LPAR2 89/4885LPAR3 171/4885LPAR1 114/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | LPAR2 406/4885LPAR3 588/4885LPAR1 616/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | LPAR2 117/4885LPAR3 441/4885LPAR1 140/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | LPAR2 173/4885LPAR3 199/4885LPAR1 262/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | LPAR2 126/4885LPAR3 135/4885LPAR1 191/4885 |
| US-20180037893-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | LPAR2 25/4885LPAR3 5/4885LPAR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.